Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication
出版年份 2021 全文链接
标题
Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication
作者
关键词
-
出版物
Blood Cancer Journal
Volume 11, Issue 2, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-02-20
DOI
10.1038/s41408-021-00429-z
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Prognostic and Predictive Molecular Biomarkers in Chronic Lymphocytic Leukemia
- (2020) Jimmy Lee et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables
- (2019) Andrew W. Roberts et al. BLOOD
- Ibrutinib and Venetoclax for First-Line Treatment of CLL
- (2019) Nitin Jain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study
- (2019) Peter Hillmen et al. JOURNAL OF CLINICAL ONCOLOGY
- Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience
- (2018) Susan O’Brien et al. BLOOD
- Mechanistic Insights into CpG DNA and IL-15 Synergy in Promoting B Cell Chronic Lymphocytic Leukemia Clonal Expansion
- (2018) Rashmi Gupta et al. JOURNAL OF IMMUNOLOGY
- Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia
- (2017) Manoj K. Kashyap et al. Journal of Hematology & Oncology
- Bruton’s tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia
- (2017) J Deng et al. LEUKEMIA
- HSP90 stabilizes B-cell receptor kinases in a multi-client interactome: PU-H71 induces CLL apoptosis in a cytoprotective microenvironment
- (2017) A Guo et al. ONCOGENE
- Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment
- (2017) Ailin Guo et al. Oncotarget
- Metabolism and Disposition of a Novel B-Cell Lymphoma-2 Inhibitor Venetoclax in Humans and Characterization of Its Unusual Metabolites
- (2016) Hong Liu et al. DRUG METABOLISM AND DISPOSITION
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
- (2016) Andrew W. Roberts et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo
- (2015) S. E. M. Herman et al. CLINICAL CANCER RESEARCH
- Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia
- (2015) F. Cervantes-Gomez et al. CLINICAL CANCER RESEARCH
- Multi-lineage potential research of bone marrow mesenchymal stem cells from Bama miniature pig
- (2015) Chunyu Bai et al. JOURNAL OF EXPERIMENTAL ZOOLOGY PART B-MOLECULAR AND DEVELOPMENTAL EVOLUTION
- TLR-9 and IL-15 Synergy Promotes the In Vitro Clonal Expansion of Chronic Lymphocytic Leukemia B Cells
- (2015) Patricia K. A. Mongini et al. JOURNAL OF IMMUNOLOGY
- Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib
- (2015) Ailin Guo et al. Oncotarget
- Co-culture of primary CLL cells with bone marrow mesenchymal cells, CD40 ligand and CpG ODN promotes proliferation of chemoresistant CLL cells phenotypically comparable to those proliferating in vivo
- (2015) Noelia Purroy et al. Oncotarget
- Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy
- (2014) J. A. Woyach et al. BLOOD
- Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells
- (2014) Jiao Ma et al. BRITISH JOURNAL OF HAEMATOLOGY
- Functional characterization of BTK C481S mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors
- (2014) S Cheng et al. LEUKEMIA
- Ibrutinib Resistance in Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Chronic Lymphocytic Leukemia Clone Disrupts the Bone Marrow Microenvironment
- (2014) Alexandre Janel et al. STEM CELLS AND DEVELOPMENT
- Biology of Chronic Lymphocytic Leukemia in Different Microenvironments
- (2013) Yair Herishanu et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity
- (2013) S Cheng et al. LEUKEMIA
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- How the microenvironment wires the natural history of chronic lymphocytic leukemia
- (2013) Federico Caligaris-Cappio et al. SEMINARS IN CANCER BIOLOGY
- “Role of the B-cell receptor and the microenvironment in chronic lymphocytic leukemia’’
- (2013) P Oppezzo et al. Blood Cancer Journal
- The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia
- (2012) M. F. M. de Rooij et al. BLOOD
- Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial
- (2012) Sebastian Böttcher et al. JOURNAL OF CLINICAL ONCOLOGY
- Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
- (2012) Ranjana H. Advani et al. JOURNAL OF CLINICAL ONCOLOGY
- Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
- (2011) S. E. M. Herman et al. BLOOD
- Unknown
- (2011) Carlo Calissano et al. MOLECULAR MEDICINE
- The lymph node microenvironment promotes B-cell receptor signaling, NF- B activation, and tumor proliferation in chronic lymphocytic leukemia
- (2010) Y. Herishanu et al. BLOOD
- Activities of SYK and PLC 2 Predict Apoptotic Response of CLL Cells to SRC Tyrosine Kinase Inhibitor Dasatinib
- (2010) Z. Song et al. CLINICAL CANCER RESEARCH
- Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia ("accelerated" chronic lymphocytic leukemia) with aggressive clinical behavior
- (2010) E. Gine et al. HAEMATOLOGICA
- Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance
- (2009) A. V. Kurtova et al. BLOOD
- Chronic lymphocytic leukemia microenvironment: shifting the balance from apoptosis to proliferation
- (2009) S. Deaglio et al. HAEMATOLOGICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started